Have you ever wondered what it’s like to be a medical oncologist? Follow our Dr. Eric Singhi throughout his day.

Eric K. Singhi, M.D.
Department of General Oncology, Division of Cancer Medicine



Featured Articles
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
2016 | Medical University of South Carolina, Charleston, South Carolina, US, M.D |
2012 | Duke University, Durham, North Carolina, US, BS in Bachelor of Science in Neuroscience |
Postgraduate Training
2019-2022 | Chief Fellow, Hematology/Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
2016-2019 | Clinical Residency, Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee |
Board Certifications
2022 | American Board of Internal Medicine - Hematology |
2022 | American Board of Internal Medicine - Medical Oncology |
2019 | American Board of Internal Medicine |
Experience & Service
Institutional Committee Activities
Committee Member, Committee for Faculty Required Training (ComFRT), 2025 - Present
Committee Member, Artificial Intelligence and Digital Health GME, 2024 - Present
Committee Member, Thoracic/Head and Neck Medical Oncology Lead for Pharmacy and Therapeutics Committee, 2024 - Present
Committee Member, Thoracic/Head and Neck Medical Oncology Lead for Clinical Effectiveness Advisory Committee, 2024 - Present
Ambassador, MD Anderson Community Ambassador for Lung Cancer, 2024 - Present
Patient Safety Quality Officer, Patient Safety Quality Officer of Thoracic Oncology Service Line, 2024 - Present
Faculty Member, Thoracic Service Line Physician Leadership, 2023 - Present
Physician Lead, Research Program/ Community Outreach & Engagement Physician Lead, 2023 - Present
Co-Chair, General Oncology Grand Rounds, 2023 - Present
Faculty Member, Clinical Competency Committee for Hematology/Medical Oncology Fellowship Program, 2023 - Present
Co-Director, Thoracic Medical Oncology Rotation for Hematology/Medical Oncology Fellowship Program, 2023 - Present
Co-Chair, Thoracic/Head and Neck Medical Oncology Journal Club, 2023 - Present
Faculty Member, Lung Cancer Center Support Grant (CCSG) Program, 2023 - Present
Honors & Awards
2025 | Emerging Leader Alumni Award, Medical University of South Carolina College of Medicine |
2024 | Rising Star of MD Anderson, The University of Texas MD Anderson Cancer Center |
2024 | Top 100 Xfluencers in Lung Cancer, OncoDaily |
2024 | Top 100 Oncologists on Social Media, Larvol Oncology Data Intelligence |
2023 | Patient Education Ambassador, Global Resource for Advancing Cancer Education |
2023 | Medical Spotlight Keynote Speaker Award, MedNews Week International |
2023 | International Association for Study of Lung Cancer (IASLC) Academy Awardee, International Association for Study of Lung Cancer (IASLC) |
2023 | Junior Faculty Travel Award, Hawaii Global Summit on Thoracic Malignancies |
2023 | MD Anderson Awesome Job Award, The University of Texas MD Anderson Cancer Center |
2022 | Young Investigator Award, EGFR Resisters Research Summit |
2022 | Patient Education Ambassador, Global Resource for Advancing Cancer Education |
2022 | MD Anderson Awesome Job Award, MD Anderson Cancer Center |
2021 | Physician Educators Certificate Program (PECP), University of Texas Health Houston |
2021 | Patient Education Ambassador, Global Resource for Advancing Cancer Education |
2016 | Gold Humanism Honor Society, Medical University of South Carolina |
2016 | Alpha Omega Alpha Honor Medical Society, Medical University of South Carolina |
2015 | Rich Merit Scholarship, Medical University of South Carolina |
2014 | Jean Wilson Endowed Merit Scholarship, Medical University of South Carolina |
2013 | Caroline B. Lown Merit Scholarship, Medical University of South Carolina |
2012 | Graduation with Distinction, Duke University |
2012 | Magna Cum Laude, Duke University |
2012 | Phi Beta Kappa, Duke University |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Owen DH, Ismaila N, Ahluwalia A, Feldman J, Gadgeel S, Mullane M, Naidoo J, Presley CJ, Reuss JE, Singhi EK, Patel JD. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3. J Clin Oncol 43(10):e2-e16, 2025. e-Pub 2025. PMID: 40014839.
- Henley, M, DeCotiis, G, FitzGibbon, H, Singhi, EK. Decoding clinical trial jargon. Future Oncology 21(1):11-14, 2025. e-Pub 2025. PMID: 39692566.
- Sridhar A, West HJ, Singhi EK. Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer 25(7):e286-e294, 2024. e-Pub 2024. PMID: 38772808.
- Mysore M, Singhi D, Singhi EK. Caring for Your Heart During Cancer Treatment. JAMA Oncol 10(10):1447, 2024. e-Pub 2024. PMID: 39207763.
- Abu Rous F, Desai A, Singhi EK. Clinical Trials for Patients With Cancer. JAMA Oncol 10(3):416, 2024. e-Pub 2024. PMID: 38270965.
- Sridhar A, West H, Singhi EK. rief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2024.
- Kareff SA, Sridhar A, Dhawan N, Anampa-Guzman A, Singhi EK, Velazquez AI. The Democratization of Hematology-Oncology Medical Education during the COVID-19 Pandemic. Cancer Invest 41(6):548-558, 2023. e-Pub 2023. PMID: 37357925.
- Singhi EK, Mott F, Worse M, Leung CH, Lee JJ, Carter B, Presley CJ, Heymach JV, Altan M. Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non-small cell lung cancer. Oncol Lett 25(6):262, 2023. e-Pub 2023. PMID: 37216156.
- Kareff SA, Sridhar A, Dhawan N, Anampa-Guzman A, Singhi EK, Velazquez AI. The democratization of hematology-oncology medical education during the COVID-19 pandemic. Cancer Investigation 0:1-9, 2023. e-Pub 2023.
- Singhi EK, Feldman J, West HJ. The Multidisciplinary Cancer Conference. JAMA Oncol 9(2):288, 2023. e-Pub 2022. PMID: 36547939.
- Abu Rous F, Singhi EK, Sridhar A, Faisal MS, Desai A. Lung Cancer Treatment Advances in 2022. Cancer Invest 41(1):1-20, 2023. e-Pub 2022. PMID: 36036470.
- Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Mott FE. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer 23(3):236-243, 2022. e-Pub 2022. PMID: 35216923.
- Hu Z, Singhi EK, Apostolidou E, Mai B, Juneja HS, Hu S. Mass-forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia. Int J Lab Hematol 43(3):e135-e137, 2021. e-Pub 2021. PMID: 33314782.
- Singhi EK, Mott F, Worst M, Borg M, Johnson D, Lewis J, etal. Clinical outcomes of immunotherapy continued beyond radiographic progression in older adults with advanced non-small cell lung cancer. Journal for Immunotherapy of Cancer, 2021. e-Pub 2021.
- Singhi EK, Dupuis MM, Ross JA, Rieber AG, Bhadkamkar NA. Medical Hematology/Oncology Fellows' Perceptions of Online Medical Education During the COVID-19 Pandemic. J Cancer Educ 35(5):1034-1040, 2020. e-Pub 2020. PMID: 32888144.
- Feld E, Singhi EK, Phillips S, Huang LC, Shyr Y, Horn L. Palliative Care Referrals for Advanced Non-small-cell Lung Cancer (NSCLC): Patient and Provider Attitudes and Practices. Clin Lung Cancer 20(3):e291-e298, 2019. e-Pub 2019. PMID: 30862422.
- Singhi EK, Moore DC, Muslimani A. Metastatic Soft Tissue Sarcomas: A Review Of Treatment and New Pharmacotherapies. P T 43(7):410-429, 2018. e-Pub 2018. PMID: 30013298.
- Patel K, Patel M, Gor A, Naidu S, Nathwani N, Kothadia R, Parekh S, Singhi EK. Oncology practice transformation helps deliver patient-centered cancer care in a community oncology practice. The American Journal of Managed Care, 2018. e-Pub 2018.
- Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, etal. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension, 2017. e-Pub 2017.
- Singhi EK, Pommerenke AW, Mushtaq S, Cummings KM, etal. Addressing tobacco use at NCI designated cancer centers: Online resources available for patients. Journal of Clinical Oncology, 2015. e-Pub 2015.
- Nikolova YS, Singhi EK, Drabant EM, Hariri AR. Reward-related ventral striatum reactivity mediates gender-specific effects of a galanin remote enhancer haplotype on problem drinking. Genes Brain Behav 12(5):516-24, 2013. e-Pub 2013. PMID: 23489876.
- Singhi EK, Dupuis MM, Ross JA, Rieber AG, Bhadkamkar NA. Medical Hematology/Oncology Fellows' Perceptions of Online Medical Education During the COVID-19 Pandemic. J Cancer Educ. PMID: 32888144.
Invited Articles
- Singhi EK, Halmos B. Deciding Between Frontline Regimens in Advanced-Stage, EGFR-Mutant NSCLC: Is There a Place for More Intense Combinations Vs Osimertinib in the Treatment Landscape?, 2024.
- Singhi EK, West HJ. Rethinking the treatment approach to resectable non-small cell lung cancer: do new approvals always translate to clinical value. ASCO Daily News, 2023. e-Pub 2023.
- Mushtaq S, Singhi EK, Stuart R. Triple-triple hit lymphoma. Case Reports in Internal Medicine, 2015. e-Pub 2015.
Other Articles
- Zhang B, Shah KB, Parma M, Wang K, Singhi EK, Lewis W, Rivera M, Altan M, Pozadzides J, Le X, Vokes N, Fossella F, O'Brien B, Wang C, Tom MC, Beckham T, Swanson T, Bronk J, Lin SH, Vega MF, Jacome J, Halliday A, Negrao M, Zhang J, Gibbons DL, Heymach JV, Byers LA, Gay CM Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report. J Thorac Oncol, 2025. PMID: 40126456.
- Singhi EK, West HJ When Practice Evolves Faster Than the Data in Early-Stage Non–Small Cell Lung Cancer. ASCO Daily News, 2022.
- Singhi EK, Gay CM Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer. Transl Lung Cancer Res 9(5):2051-2058, 2020. PMID: 33209625.
- Singhi EK, Horn L, Sequist LV, Heymach J, Langer CJ Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. Am Soc Clin Oncol Educ Book 39:e187-e197, 2019. PMID: 31099642.
- Singhi EK, Li BC, Denny JC Simmering Below the Surface: Sweet's Syndrome with Multiple Myeloma. Am J Med 131(9):1058-1060, 2018. PMID: 29729238.
- Singhi EK, Horn L Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer. Future Oncol 14(18):1781-1787, 2018. PMID: 29506392.
- Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension 71(2):e1-e8, 2018. PMID: 29279311.
Editorials
- Singhi EK. Disseminated Intravascular Coagulation (DIC). Vanderbilt University Medical Center Commodore Compendium, 2019.
Books (edited and written)
- Abu Rous, F, Desai, A, Singhi, EK. Clinical Trials for Patients With Cancer, 2024.
Selected Presentations & Talks
National Presentations
- 2024. 2024 Masters in Thoracic Oncology Summit. Invited. Obrixtamig US Medical National Advisory Board at MaTOS. Lake Tahoe, California, US.
- 2024. End Lung Cancer Now. Invited. McHenry-Sherman Scholarly Conference. Indianapolis, Indiana, US.
- 2024. Understanding and Managing Compassion Fatigue in Medical Practice, IASLC World Conference on Lung Cancer Selected Workshop. Invited. World Conference Lung Cancer. San Diego, California, US.
- 2024. Exploring HER2 in NSCLC: Defining Gaps and Current Practices. Invited. Medscape Oncology, US.
- 2024. Binaytara Foundation Best of ASCO 2024: Updates in Small Cell Lung Cancer. Albuquerque, New Mexico, US.
- 2024. Case Based Roundtable: Immunotherapy in NSCLC-Virtual. Invited. Targeted Oncology, US.
- 2024. Leveraging Social Media for Career Growth. Expert Faculty Panelist ASCO 2024 Annual Meeting. Chicago, Illinois, US.
- 2024. “The Priciest Thing to Do Is to Blindly Treat” NSCLC, US.
- 2024. If You Have “One Shot on Goal” in EGFR-Mutated NSCLC, Which Approach Is Best?, US.
- 2024. Navigating Advocacy, Mentorship, and More in NSCLC Management. OncLive with MedNewsWeek, US.
- 2024. ASCO Virtual Mentoring Program, US.
- 2024. “Basics” of Lung Cancer for the Community. Invited. Houston, Texas, US.
- 2024. Early-Career Round Table Session. Invited. Santa Monica, California, US.
- 2024. Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice. Coral Gables, Florida, US.
- 2023. Biomarker Testing in Non-Small Cell Lung Cancer: Practical Application. OncLive. Houston, Texas, US.
- 2023. Meharry Medical College Medical Grand Rounds: Making the Right Call- Biomarker Testing and Targeting in NSCLC. Nashville, Tennessee, US.
- 2023. WCLC23 Interview Research Updates, US.
- 2023. OncLive Biomarker Consortium for Lung Cancer. Nashville, Tennessee, US.
- 2023. Immunotherapy-Induced Encephalitis: A Case of a Rare but Serious Complication of Anti-PD-1 Treatment. MD Anderson Cancer Center IOTOX Research Retreat. Houston, Texas, US.
- 2023. Tailoring the treatment approach to resectable stage non-small cell lung cancer. Invited. Binaytara Foundation 2023 Updates on Hematology and Oncology. Houston, Texas, US.
- 2023. Clinical outcomes of immunotherapy continued beyond radiographic progression in older adult patients with advanced non-small cell lung cancer. Conference. DAVA Oncoloy. Kona, HI, US.
- 2023. Chair: Locally Advanced NSCLC. Conference. Chair: Locally Advanced NSCLC. Santa Monica, CA, US.
- 2022. Testing for Targetable Mutations in NSCLC: Tissue vs. Liquid Biopsy. VuMedi, US.
International Presentations
- 2023. Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective. Conference. Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective, SG.
Formal Peers
- 2025. Management of Metastatic Non Small Cell Lung Cancer with Driver Alterations: What to know in 2025. Houston, Texas, US.
- 2025. Management of Metastatic Non Small Cell Lung Cancer without Driver Alterations: What to know in 2025. Houston, Texas, US.
- 2024. Navigating Social Media: Overview for the Online Oncologist. Houston, Texas, US.
- 2024. Pulmonary Medicine Fellows Board Review: Lung Cancer. Houston, Texas, US.
- 2024. The Truth About Tobacco and Vaping. Houston, Texas, US.
- 2024. Tailoring the treatment approach to resectable non small cell lung cancer BTF's 2023 Updates on Hematology & Oncology. Houston, Texas, US.
- 2024. Management of Metastatic Non Small Cell Lung Cancer with Driver Alterations. Houston, Texas, US.
- 2024. Management of Metastatic Non Small Cell Lung Cancer without Driver Alterations. Houston, Texas, US.
- 2024. Lung Cancer Board Review Lecture. Houston, Texas, US.
- 2024. Treatment of Early-Stage and Locally Advanced NSCLC: A Chalk Talk for Oncology Fellows. Houston, Texas, US.
- 2024. MD Anderson Fellowship Journal Club Discussion: Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases Expert Medical Oncology Discussant. Houston, Texas, US.
- 2024. Lung Cancer Comprehensive Care Overview Nurses and Allied Healthcare Professionals Didactic Series. Houston, Texas, US.
- 2024. Treatment of Stage I to III NSCLC: Fellowship Didactic Talk. Houston, Texas, US.
- 2024. Immunotherapy in the management of patients with metastatic non-small cell lung cancer. Houston, Texas, US.
- 2023. Navigating Social Media: A Guide for the Online Oncologist. Invited. Navigating Social Media: A Guide for the Online Oncologist. Houston, TX, US.
- 2023. Tailoring the treatment approach to resectable non small cell lung cancer. Invited. Tailoring the treatment approach to resectable non small cell lung cancer. Houston, TX, US.
- 2023. Navigating Social Media as an Oncologist. Invited. Navigating Social Media as an Oncologist. Houston, TX, US.
Grant & Contract Support
Date: | 2024 - 2025 |
Title: | “Investigating Clinical Outcomes in Young Adults with Non-Small Cell Lung Cancer,” Rexanna's Foundation for Fighting Lung Cancer |
Funding Source: | Victor Elias Research Grant Funded Project |
Role: | PI |
Date: | 2024 - Present |
Title: | A Pilot study to assess the Concordance Between MyBreathPrint Device results and Tissue Biopsy in patients with suspected lung cancer: Single center, single arm, prospective, observational design |
Funding Source: | N/A |
Role: | Co-PI |
Patient Reviews
CV information above last modified April 11, 2025